Loading...

ONCOTELIC THERAPEUTICS INC Management Changes 8-K Filing

NCTL

ONCOTELIC THERAPEUTICS INC

()

2026 8-K

Joint Development Agreement

Product Launch Announcement

Research Presentation

Financing Agreement

Stock Agreement Details

Milestone Amendment

Contract Amendment

Funding Agreement Completed

Debt Financing Agreement

Access to Research Tools

Investment Offering Details

Investor Presentation Update

Equity Offerings

Presentation Announcement

External Links:

On January 22, 2026, Oncotelic Therapeutics, Inc. announced a restricted stock agreement with CEO Dr. Vuong Trieu, potentially issuing up to 26,512 shares of convertible Series A Preferred Stock based on performance milestones aimed at improving the company's capital structure.

AI Assistant

ONCOTELIC THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.